AbSci receives undisclosed investment from Merck GHI to advance 'Protein Printing'; SEC filing shows $70M cash infusion
Vancouver, Wash. biotech AbSci raised an undisclosed investment from Merck’s Global Health Innovation Fund, which manages $500 million, to advance its 'Protein Printing' technology for discovering and manufacturing complex biologics. A Feb. 26 SEC filing notes a $70 million cash infusion; AbSci previously raised $65 million in October and acquired Denovium in January.